Follow the product label or your healthcare practitioner's advice for the correct dose
Lastly, tirzepatide, a new gastric inhibitory polypeptide (GIP)+GLP-1 therapy for diabetes, could not be included in this analysis as it became commercially available in 2023
At Set Point, we believe in personalized treatment plans, as we know that every patients journey is different
Thats why its important to speak with a healthcare professional, like a Midi clinician, before applying to enroll in a study to make sure its a safe option for your wellness journey
Is 1015% weight loss realistic for most people
95% CI, 1.21-1.93), subcutaneous semaglutide (HR = 1.22